AI Summary & Key Takeaways
AI InsightEleven patients received neoadjuvant and thirty-nine patients received adjuvantchemotherapy.Results: At a median follow-up 43 months (range: 2–76) the estimated 5-year overall survival and disease-free survival were 74.6% and62.6%, respectively.Conclusion: In radiotherapy of advanced NPC, generally a considerable amount of normal head and neck tissues might have to beirradiated in addition to gross tumor volume, involved node, and elective neck irradiation.
📌 3 Key Takeaways
Abstract
Background/aim: To assess the efficacy and side effects of concurrent weekly chemotherapy and radiotherapy with simultaneousintegrated boost (SIB) technique for nasopharyngeal cancer (NPC).Materials and methods: A total of 51 consecutive patients with diagnosis of NPC were treated between February 2010 and December2015. The median dose for PTV70 (range: 60–82) was given in 33 fractions (range: 31–35). Forty-five of the patients received concomitantweekly chemotherapy between 3–7 cycles (median 6). Eleven patients received neoadjuvant and thirty-nine patients received adjuvantchemotherapy.Results: At a median follow-up 43 months (range: 2–76) the estimated 5-year overall survival and disease-free survival were 74.6% and62.6%, respectively.Conclusion: In radiotherapy of advanced NPC, generally a considerable amount of normal head and neck tissues might have to beirradiated in addition to gross tumor volume, involved node, and elective neck irradiation. Together with chemoradiotherapy, poor oralhygiene and inadequate nutritional support result in excessive morbidity. Despite loco-regional success of concurrent chemoradiotherapy,distant metastasis is still the major pattern of treatment failure in the intensity modulated radiotherapy era. We need to improve ouradjuvant chemotherapy regimens or develop new drugs.